Key result
Rituximab treatment for 1 year did not significantly change arterial stiffness measured by pulse wave velocity (8.1 m/s at baseline vs 8.0 m/s at 1 year; P=0.924) in patients with active RA.
Why the study?
Does rituximab treatment improve arterial stiffness and cardiovascular risk factors in patients with active rheumatoid arthritis?
Population
33 patients with active rheumatoid arthritis, mean age 60.9, 29 females. 30 had positive RFs, 27 positive…
Design
Cohort
Follow-up
1 year
Authors
Loading...
No change in arterial stiffness after rituximab in active RA; leaves open effects on cardiovascular outcomes.
Observational (n=33)
Does rituximab treatment improve arterial stiffness and cardiovascular risk factors in patients with active rheumatoid arthritis?
Absolute Event Rate: 8% vs 8.1%
p-value: p=0.924
Rituximab treatment in active rheumatoid arthritis effectively reduces inflammation but does not improve arterial stiffness and may lead to a pro-atherogenic lipid profile.
Mathieu et al. (2012) conducted an observational in Rheumatoid arthritis (n=33). Rituximab vs. Baseline was evaluated on Arterial stiffness measured by pulse wave velocity (PWV) (p=0.924). Rituximab treatment for 1 year did not significantly change arterial stiffness measured by pulse wave velocity (8.1 m/s at baseline vs 8.0 m/s at 1 year; P=0.924) in patients with active RA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: